While advances in cell and gene therapies chip away at the need for bone marrow transplants, the transplantation field remains very much alive and in the midst of innovations of its own.
Fresh from reporting encouraging results with its oral weight-loss drug, Terns Pharma has moved swiftly ahead with a public offering, seeking to raise upwards of $125 million to fund additi